ChemoMetec Valuation

Q: What is the Fair Price of CHEMM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

CHEMM (DKK374.6) is trading above our estimate of [[fair value]] (DKK256.12)

Is CHEMM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CHEMM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CHEMM (DKK374.6) is trading above our estimate of fair value (DKK256.12)

Significantly Below Fair Value: CHEMM is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CHEMM?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for CHEMM. This is calculated by dividing CHEMM's market cap by their current preferred multiple.
What is CHEMM's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	DKK 6.52b

CHEMM key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	15.7x
Enterprise Value/EBITDA	32.7x
PEG Ratio	4.1x

Price to Earnings Ratio vs Peers

How does CHEMM's PE Ratio compare to its peers?

The above table shows the PE ratio for CHEMM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	52.9x
603108 Shanghai Runda Medical Technology	44.7x	n/a	CN¥8.5b
ERGO Ergomed	46.7x	14.2%	UK£701.1m
ALK B ALK-Abelló	57.4x	18.2%	DKK 39.6b
BIOT Biotage	62.9x	19.9%	SEK 15.8b
CHEMM ChemoMetec	45.3x	11.1%	DKK 6.5b

Price-To-Earnings vs Peers: CHEMM is good value based on its Price-To-Earnings Ratio (45.3x) compared to the peer average (55x).

Price to Earnings Ratio vs Industry

How does CHEMM's PE Ratio compare vs other companies in the European Life Sciences Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	25.4%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	25.4%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: CHEMM is expensive based on its Price-To-Earnings Ratio (45.3x) compared to the European Life Sciences industry average (43x).

Price to Earnings Ratio vs Fair Ratio

What is CHEMM's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CHEMM PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	45.3x
Fair PE Ratio	23.9x

Price-To-Earnings vs Fair Ratio: CHEMM is expensive based on its Price-To-Earnings Ratio (45.3x) compared to the estimated Fair Price-To-Earnings Ratio (23.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CHEMM forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	DKK 374.60	DKK 462.50 +23.5%	2.7%	DKK 475.00	DKK 450.00	n/a	2
Aug ’25	DKK 377.40	DKK 437.50 +15.9%	8.6%	DKK 475.00	DKK 400.00	n/a	2
Jul ’25	DKK 301.40	DKK 437.50 +45.2%	8.6%	DKK 475.00	DKK 400.00	n/a	2
Jun ’25	DKK 363.20	DKK 437.50 +20.5%	8.6%	DKK 475.00	DKK 400.00	n/a	2
May ’25	DKK 294.80	DKK 462.50 +56.9%	13.5%	DKK 525.00	DKK 400.00	n/a	2
Apr ’25	DKK 423.80	DKK 451.67 +6.6%	19.2%	DKK 525.00	DKK 330.00	n/a	3
Mar ’25	DKK 507.00	DKK 451.67 -10.9%	19.2%	DKK 525.00	DKK 330.00	n/a	3
Feb ’25	DKK 363.60	DKK 448.33 +23.3%	20.4%	DKK 525.00	DKK 320.00	n/a	3

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.